Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Mirum Pharmaceuticals, Inc.. A complete text table follows the diagram.
Livmarli leads product sales, with the broader bile-acid medicines portfolio completing the platform.
Swipe to explore
Labels and displayed flow values are reported filing values or exact disclosed subtotals.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Mirum Pharmaceuticals revenue | 1 | $160M | $159.9M reported quarterly revenue |
| Livmarli | 2 | $114M | 71% of product sales |
| Bile Acid Medicines | 2 | $46.1M | 29% of product sales |
| From | To | Value |
|---|---|---|
| Mirum Pharmaceuticals revenue | Livmarli | $114M |
| Mirum Pharmaceuticals revenue | Bile Acid Medicines | $46.1M |